STAT Plus: Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’
I logged into a Zoom meeting wearing a fuzzy robe. Greetings and welcome to another semi-regular column on the Covid-19 pandemic. In this edition: Will #JPM21 be a thing? Some straight talk from Alexis Borisy, Daphne Zohar, and Abbie Celniker; and another biotech buyside investor survey.
Three months ago, thousands of biopharma people and related hangers-on (including a bunch of STAT journalists) were packing suitcases and preparing to board planes to San Francisco. We were all traveling to the annual J.P Morgan Healthcare Conference and the orbiting meetings and festivities that make “JPM Week” the industry’s largest convocation.
